Abstract：Objective To observe and analyze the related influencing factors of anxiety, depression and cognitive impairment in Parkinson’s disease (PD) patients. Methods A total of 92 PD patients diagnosed in the Department of Movement Disorders, Neurology Center, Beijing Tiantan Hospital, Capital Medical University from January to October 2016 were selected. The unified Parkinson’s disease rating scale (UPDRS), modified Hoehn-Yahr staging scale, Hamilton anxiety scale, Hamilton depression scale, and the Montreal cognitive assessment scale (MoCA) were evaluated. The incidence of anxiety, depression and cognitive dysfunction in PD patients was understood, and the risk factors associated with anxiety, depression and cognitive dysfunction in PD patients were analyzed and discussed. Results In this group, 92 PD patients with anxiety accounted for 77.17%. The patients with depression accounted for 69.57%. Logistic regression results showed that male was a protective factor for PD patients with anxiety (OR = 0.24, P = 0.048), the long course of disease was a risk factor for PD patients with anxiety (OR = 1.36, P = 0.019), male (OR = 0.22, P = 0.013) and advanced age (OR = 0.95, P = 0.041) were protective factors for PD patients with depression (OR = 0.22, P = 0.013), high UPDRS score was a risk factor for PD patients with depression (OR = 1.08, P = 0.007). MoCA score showed that 78.26% of the patients had cognitive dysfunction. Logistic regression results showed that long years of education was a protective factor for cognitive dysfunction in PD patients (OR = 0.70, P < 0.003). Conclusion Anxiety, depression and cognitive impairment are all common non-exercise symptoms of PD patients with a high incidence and are easily affected by age, gender, course of disease, years of education and other factors, while non-exercise symptoms have a significant impact on the overall treatment effect and quality of life of patients.
[1] 马芹颖，张晓曼，张忠霞，等.帕金森病认知功能障碍的影响因素研究[J].新医学，2019，50（7）：510-514.
[2] 顾翠，冯磊，王继华，等.帕金森病合并认知功能障碍患者血清胱抑素C及尿酸水平的变化及意义[J].中国临床医生杂志，2018，46（12）：1456-1458.
[3] 李振光，于占彩，于成勇，等.早期帕金森病患者非运动症状的临床表现[J].中华神经科杂志，2015，48（8）：672-676.
[4] Jones JD，Butterfield LC，Song W，et al. Anxiety and depression are better correlates of Parkinson’s disease quality of life than apathy [J]. J Neuropsychiatry Clin Neurosci，2015，27（3）：213-218.
[5] 王舜，毛善平，腊琼，等.帕金森病伴发抑郁和焦虑及其相关因素研究[J].海南医学，2017，28（1）：50-53.
[6] Ng A，Chander RJ，Tan LC，et al. Influence of depression in mild Parkinson’s disease on longitudinal motor and cognitive function [J]. Parkinsonism Relat Disord，2015，21（9）：1056-1060.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森及运动障碍专业.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[8] Goetz CG. Movement disorder society-unified Parkinson’s disease rating scale（MDS-UPDRS）：a new scale for the evaluation of Parkinson’s disease [J]. Rev Neurol（Paris），2010，166（1）：1-4. doi：10.1016/j.neurol.2009.09.001.
[9] Goetz CG，Poewe W，Rascol O，et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale：status and recommendations [J]. Mov Disord，2004， 19（9）：1020-1028. doi：10.1002/mds.20213.
[10] Maier W，Buller R，Philipp M，et al. The Hamilton Anxiety Scale：reliability，validity and sensitivity to change in anxiety and depressive disorders [J]. J Affect Disord，1988， 14（1）：61-68. doi：10.1016/0165-0327（88）90072-9.
[11] Vindbjerg E，Makransky G，Mortensen EL，et al. Cross-cultural psychometric properties of the Hamilton depression rating scale [J]. Can J Psychiatry，2019，64（1）：39-46. doi：10.1177/0706743718772516.
[12] Nasreddine ZS，Phillips NA，Bédirian V，et al. The Montreal Cognitive Assessment，MoCA：A Brief Screening Tool For Mild Cognitive Impairment [J]. J Am Geriatr Soc，2005，53（4）：695-699. doi：10.1111/j.1532-5415. 2005.53221.x.
[13] Armstrong MJ，Okun MS. Diagnosis and treatment of Parkinson’s disease：a review [J]. JAMA，2020，323（6）：548-560. doi：10.1001/jama.2019.22360.
[14] 李雅博.脑动脉硬化与帕金森综合症的相关性研究[J].中西医结合心血管病杂志，2016，4（18）：124.
[15] 刘越存，黎展鸿，陈雄辉.美多芭联合盐酸普拉克索治疗对帕金森患者焦虑抑郁状态及血清炎症因子水平的影响[J].中国医药科学，2017，7（7）：12-15.
[16] 袁德智，胡洁，赵秋叶，等.帕金森病进展速度与抑郁、睡眠障碍的相关性分析[J].中国医科大学学报，2020， 46（4）：326-330.
[17] Devos D，Moreau C. Opicapone for motor fluctuations in Parkinson’s disease [J]. Lancet Neurol，2016，15（2）：127-128. doi：10.1016/S1474-4422（15）00346-4.
[18] 房进平，冯涛.帕金森病焦虑的发病机制及研究进展[J].中华老年心脑血管病杂志，2016，18（7）：774-776.
[19] 郭金涛，郭雅聪，牛好敏，等.艾司西酞普兰治疗帕金森症合并焦虑和抑郁患者的疗效及对其认知功能的影响[J].国际精神病学杂志，2019，46（2）：319-321.
[20] 侯杰.氟西汀联合奥氮平对帕金森病伴抑郁患者的疗效及P300的影响[J].临床研究，2019，27（9）：49-51.
[21] 范秀博，李毓新，吉智，等.奥匹卡朋联合左旋多巴治疗帕金森病的疗效及安全性分析[J].疑难病杂志，2019， 18（2）：114-118.
[22] 唐骏.原发性帕金森病患者认知功能障碍与脑动脉硬化相关性研究[J].中国当代医药，2018，25（10）：62-64.
[23] 南彩，王高华，王晓萍，等.首发抑郁症患者事件相关电位P300及脑网络连接特征分析[J].中华行为医学与脑科学杂志，2015，24（4）：326-328.
[24] 刘疏影，陈彪.帕金森病流行现状[J].中国现代神经疾病杂志，2016，16（2）：98-101.
[25] 顾嘉晨，金桃，桂雅星.帕金森病伴轻度认知功能障碍的研究进展[J].神经疾病与精神卫生，2019，19（2）：199-204.
[26] 赵鸿飞，罗辉兰，冯珍珍，等.盐酸帕罗西汀治疗帕金森合并抑郁和焦虑患者的疗效及安全性[J].国际精神病学杂志，2017，20（3）：480-482.
京公网安备 11010502046598号